Cresco Labs Inc. (OTCMKTS:CRLBF) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Cresco Labs Inc. (OTCMKTS:CRLBF) has been assigned a consensus rating of “Moderate Buy” from the eight analysts that are presently covering the firm, MarketBeat reports. Four investment analysts have rated the stock with a hold rating, two have assigned a buy rating and two have issued a strong buy rating on the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $2.50.

Several analysts have recently commented on the company. Roth Capital upgraded Cresco Labs to a “strong-buy” rating in a report on Sunday, November 10th. Cormark cut Cresco Labs from a “moderate buy” rating to a “hold” rating in a report on Monday, November 11th. Finally, Atb Cap Markets cut Cresco Labs from a “strong-buy” rating to a “hold” rating in a report on Monday, December 9th.

Cresco Labs Price Performance

Shares of CRLBF stock opened at $0.95 on Friday. The stock’s fifty day moving average is $1.34 and its 200-day moving average is $1.55. The company has a debt-to-equity ratio of 1.80, a quick ratio of 1.39 and a current ratio of 1.97. The stock has a market capitalization of $463.73 million, a PE ratio of -4.76 and a beta of 1.73. Cresco Labs has a 52 week low of $0.90 and a 52 week high of $2.65.

Cresco Labs Company Profile

Cresco Labs Inc, together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States. It provides cannabis in flowers, vape pens, live resins, disposable pens, and extracts under the Cresco brand; vape carts, vape pens, flower, popcorn, shake, pre-rolls, shorties, and concentrates under the High Supply brand; vapes and gummies under the Good News brand; vapes and edibles under the Wonder Wellness Co brand; and tinctures, capsules, salves, and sublingual oils under the Remedi brand.